Piper Sandler expects the challenges weighing on veterinary medicine to persist through 2027, according to the firm's outlook reported by Investing.com Nigeria. That timeline — roughly two more years of pressure — is the central projection in the analysis, and it sets a planning horizon for practices, distributors, and manufacturers debating whether current softness is cyclical or structural.

The forecast frames what many clinics have experienced since the post-pandemic normalization of visit volumes: slower revenue growth, tighter client spending, and pressure on the pipeline that supplies pharmaceuticals, diagnostics, and equipment to the profession.

What does the 2027 timeline mean for practices?

For practice owners, a multi-year horizon of difficult conditions argues against betting on a quick rebound. Budgeting decisions — hiring, expansion, equipment purchases, and pricing strategy — now carry a longer risk window than many operators assumed when visit growth first decelerated.

Industry analysts have tracked a broader cooldown across the sector, and Piper Sandler's projection extends that narrative with a specific endpoint. An outlook stretching to 2027 signals the firm views current pressures as embedded rather than transitory.

Who is affected?

The projection carries implications across the veterinary economy:

• Companion-animal practices facing sustained pressure on client visit frequency and discretionary spending
• Animal-health companies and distributors whose revenue growth depends on clinic traffic and product volume
• Investors weighing positions in veterinary stocks, for whom the 2027 horizon shapes valuation assumptions

Why the forecast matters now

Equity research timelines influence capital allocation well before the forecast period ends. If lenders, private-equity buyers, and corporate consolidators accept the through-2027 view, financing terms for practice acquisitions and expansions could reflect a longer recovery assumption.

Piper Sandler's analysis joins a series of sector assessments tracking decelerating growth in veterinary services after the surge of 2020–2022. The firm's willingness to put a date on the duration of the downturn gives the industry a concrete benchmark against which to measure incoming quarterly data on visits, revenue per patient, and product sales.

Whether the sector outperforms or undershoots that 2027 endpoint will depend on variables the forecast cannot fully capture — consumer spending, pet ownership trends, and innovation in the animal-health pipeline. For now, the operating assumption from one major Wall Street firm is clear: the difficult environment in veterinary medicine has years left to run.